SK C&C wins Korea’s nod for brain infarct diagnosis AI solution

SK Inc C&C (SK C&C), the information technology service unit of South Korea’s SK Group, said on Thursday it has secured medical device approval for its brain infarct diagnosis artificial intelligence solution from the Ministry of Food and Drug Safety.

SK C&C said Medical Insight+ Brain Infarct can learn the medical image data of thousands of cerebral infarction patients with the company’s deep learning algorithm. To improve its accuracy, the company also asked neuroradiologists at renowned local medical institutions such as the Seoul National University Hospital to verify the solution’s diagnoses.

The solution analyzes non-contrast head computed tomography (CT) scans in seconds to detect brain abnormalities. It presents the possibility of brain infarction as a percentage while dividing the possible severity into seven categories to help medical staff quickly assess patients’ conditions.

The Medical Insight+ Brain Infarct also marks abnormal parts with heat maps or outlines to allow doctors to check out small areas, in which things can be easily missed.

SK C&C said it will reduce the time for stroke diagnoses if used in conjunction with Medical Insight+ Brain Hemorrhage, its AI solution for the disease that allows doctors to read both cerebral hemorrhages and infarctions at once.

The company secured separate medical device approval for Medical Insight+ Brain Hemorrhage in 2021 from the MFDS.

Write to Kyung-Ju Kang at callme@hankyung.com
 

Jongwoo Cheon edited this article.